Article | February 17, 2021

Why A Modular Continuous Pilot Plant Might Be Your Flow Chemistry Solution

By Dr. Ingo Klement, Director Global Business Development for Exclusive Synthesis, Evonik

Evonik-lab-feature

Momentum continues to build behind the use of flow chemistry to overcome many of the process limitations of batch manufacturing for APIs and advanced intermediates. Thanks to more than two decades of collaboration between manufacturers, academia and regulatory authorities, the foundation stones have been laid to integrate flow chemistry into the process development and cGMP manufacturing of such substances made by chemical synthesis.

Several drug products utilizing continuous processes have now been approved by the FDA, with many more in the clinical development pipeline. On the drug substance side however, despite much progress, there are still very few companies that have been able to successfully scale-up an API or intermediate with one or more continuous chemical process steps beyond the kilogram range under cGMP conditions. There are multiple factors behind this lack of commercial progress.

VIEW THE ARTICLE!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.

Subscribe to Pharmaceutical Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Pharmaceutical Online